SPRAVATO® vs Ketamine: Which Rapid-Acting Antidepressant Is Right for You?

Spravato vs Ketamine: Which Rapid-Acting Antidepressant Is Right for You?

Table of Contents

1. Quick Comparison: Spravato vs Ketamine
2. FDA Approval & Legal Status
3. Route of Administration
4. REMS vs No REMS
5. Efficacy & Response Rates
6. Dissociation & Side Effects
7. Cognitive Safety: Long-Term Implications
8. Insurance Coverage & Cost
9. Which Is Right for You?
10. Frequently Asked Questions

Key Takeaways

• Spravato is FDA-approved (2019), intranasal, REMS-regulated, self-administered in office; Ketamine is off-label, IV, no REMS, clinician-administered
• Efficacy: Spravato 25–65% response rate; IV ketamine estimated 40–70%, though less robust FDA data
• Dissociation: Spravato 41% (monitored 2-hour window); IV ketamine more intense but also monitored
• Long-term cognition: Esketamine (Spravato) maintains/improves cognition; racemic ketamine may impair cognition chronically
• Insurance: Most major insurers cover Spravato; IV ketamine often out-of-pocket
• Cost: Spravato ~$179/dose (self-pay); IV ketamine $500–1,000/session (often uninsured)
• Best for Spravato: TRD with multiple failed trials, acute suicidal ideation, preference for intranasal, good insurance
• Best for Ketamine: Higher efficacy expectations, prefer IV, no REMS restrictions, willing to self-pay, access to experienced ketamine clinic

Quick Comparison: Spravato vs Ketamine

Both Spravato (intranasal esketamine) and IV ketamine are rapid-acting antidepressants that work on the glutamatergic system, offering hope for treatment-resistant depression. However, they differ significantly in FDA approval status, administration route, regulatory requirements, cognitive safety, and cost.

Side-by-Side Overview

FDA Approval & Legal Status

Spravato: FDA-Approved Medication

Spravato (esketamine) was approved by the FDA on September 20, 2019 for treatment-resistant depression, making it the first and only FDA-approved intranasal rapid-acting antidepressant. It is indicated only for treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior, and must be administered in a REMS-certified setting with monitoring. This approval came after rigorous Phase 3 randomized controlled trials demonstrating:

• Efficacy for TRD: Significant symptom reduction compared to placebo in patients with failed antidepressant trials
• Efficacy for Suicidal Crisis: Rapid reduction in suicidal ideation/behavior within hours

The FDA approval means:

• Evidence-based: Spravato's safety and efficacy are validated through large-scale clinical trials
• Insurance coverage: Most insurance companies recognize FDA-approved status and cover the treatment
• Quality standards: Manufacturing, purity, and dosing are standardized under FDA oversight
• Medical liability: FDA approval provides regulatory protection for prescribers and patients

IV Ketamine: Off-Label Use

IV ketamine is not FDA-approved for depression treatment. Instead, ketamine is:

• FDA-approved for anesthesia only (1970s approval for surgical use)
• Used off-label for depression: Based on clinical experience and growing evidence, but without formal FDA indication
• Variable regulation: Each clinic operates under their own protocols; no standardized REMS program
• Insurance limitations: Off-label status means most insurance companies will not cover IV ketamine, requiring out-of-pocket payment

The off-label use of ketamine for depression is legal and increasingly common, supported by meta-analyses and real-world evidence. However, it lacks the regulatory oversight and insurance coverage of FDA-approved treatments.

Route of Administration

Spravato: Intranasal Self-Administration

Spravato is self-administered as a nasal spray in a REMS-certified physician's office:

• Self-delivery: Patient uses a metered-dose applicator to spray medication into each nostril
• Healthcare provider oversight: Clinician directly observes administration and is present throughout 2-hour monitoring
• No IV line required: Non-invasive; eliminates vein access concerns
• Faster administration: 5–10 minutes from arrival to dose completion
• Accessibility: Intranasal route is less intimidating for some patients fearful of IV needles

Advantages: Non-invasive, rapid administration, patient control, reduced anxiety for needle-phobic patients

Disadvantages: Nasal tolerance/irritation with repeated dosing, potential mucociliary clearance variation, possible dosing inconsistency with nasal obstruction

IV Ketamine: Intravenous Administration

IV ketamine is administered through an intravenous line, typically by a nurse or clinician in a specialized ketamine clinic:

• Clinician-administered: Healthcare provider places IV line and infuses medication over 40–60 minutes
• Direct bloodstream access: Ensures complete and consistent medication delivery
• Pharmacokinetic predictability: IV route provides more consistent drug levels
• Higher intensity dissociation: IV administration produces more intense, faster-onset dissociative effects (within 5–15 minutes)

Advantages: Direct drug delivery, pharmacokinetically predictable, potentially faster onset, higher perceived intensity

Disadvantages: Invasive (requires IV line), vein access challenges, higher dissociation burden, longer infusion time (40–60 min vs 5–10 min), greater vascular complications risk

REMS vs No REMS

Spravato: FDA REMS Program

Spravato operates under a strict Risk Evaluation and Mitigation Strategy (REMS) program, meaning:

• Certified Pharmacy: Medications distributed only through REMS-certified pharmacies
• Certified Providers: Healthcare providers must be REMS-certified to administer
• Certified Facilities: Administration must occur in REMS-certified office settings
• Patient Training: All patients must complete REMS education before treatment
• Office Administration Only: Spravato cannot be taken home or self-administered outside a medical facility
• Monitoring Requirement: 2-hour supervised post-administration monitoring is mandatory
• Structured Reporting: All adverse events reported to the REMS database

Why REMS for Spravato?

• Dissociation and sedation common; unmonitored use could lead to falls, accidents, impaired judgment
• Blood pressure elevation risk; monitoring allows immediate intervention
• Need to ensure safe use of a novel, rapid-acting medication

Impact on Patients: REMS makes Spravato less convenient (must visit office, cannot take home) but ensures standardized safety protocols and medical oversight.

IV Ketamine: No REMS Program

IV ketamine operates without an FDA REMS program, meaning:

• Provider discretion: Each ketamine clinic develops its own protocols and monitoring standards
• Variable safety standards: Safety procedures vary widely clinic-to-clinic
• Home infusion possible: Some clinics offer home infusions of ketamine (though not standard)
• Minimal regulatory oversight: No federal requirement for certified facilities or providers
• Patient freedom: No government-mandated patient education or agreement required

Potential Advantages: More flexibility in treatment scheduling, potentially more clinics available, less bureaucratic burden

Potential Disadvantages: Less standardized safety monitoring, variable quality between clinics, higher risk of adverse events, inconsistent medical oversight

Efficacy & Response Rates

Spravato Response Rates

Clinical trials for Spravato in TRD have shown:

• Overall response rate: 25–65% (varies by trial and definition of "response")
• Remission rate: 20–35% (significant symptom reduction or full remission)
• Onset: Response may occur within 2–4 hours of first dose; full benefit emerges over 4 weeks
• Maintenance: 70–80% of initial responders maintain benefit with continued treatment

Key Trial Data:

• TRANSFORM-1 & TRANSFORM-2 (Phase 3): Spravato + antidepressant vs. placebo + antidepressant showed statistically significant improvement in TRD patients
• SUSTAIN-1 & SUSTAIN-2 (maintenance): Long-term benefit sustained with continued dosing

IV Ketamine Response Rates

IV ketamine efficacy estimates vary because most data comes from clinical practice rather than FDA-regulated trials:

• Estimated response rate: 40–70% (based on real-world reports and smaller studies)
• Remission rate: 30–50% (varies widely by clinic and patient population)
• Onset: Rapid within 1–2 hours of infusion; some effects within 30 minutes
• Maintenance: Relapse risk higher with ketamine than Spravato; relapse can occur within days to weeks of stopping treatment

Why the Uncertainty?

• Off-label use means fewer large randomized controlled trials
• Variable patient selection between clinics (some pre-select sicker populations, improving apparent efficacy)
• Different dosing protocols, infusion durations, and follow-up schedules make comparison difficult
• Publication bias: Successful cases may be more likely reported than failures

Clinical Bottom Line: IV ketamine may have slightly higher efficacy than Spravato based on anecdotal reports, but robust FDA-grade data is lacking. Spravato's FDA-approved efficacy range (25–65%) should not be viewed as "lower" than ketamine—rather, it represents validated clinical evidence.

Dissociation & Side Effects

Spravato Dissociation Profile

Dissociation is the most common adverse effect of Spravato:

• Incidence: 41% of patients vs. 9% placebo
• Onset: 5–20 minutes post-administration
• Peak: 30–60 minutes
• Duration: Resolves by end of 2-hour monitoring period; nearly complete resolution
• Description: Feeling "floaty," detached from body, altered perception, mild depersonalization
• Severity: Generally mild-to-moderate; severe dissociation rare
• Management: Reassurance, continued monitoring; cognitive dissociation resolves completely

Other Common Spravato Adverse Effects:

• Dizziness (29%)
• Nausea (28%)
• Sedation (23%)
• Vertigo (23%)
• Hypertension (10%)

Safety Profile: Because Spravato is administered in a monitored setting for 2 hours, dissociation and other side effects are observed and managed in real-time. By discharge, patients are oriented, cognitively intact, and safe.

IV Ketamine Dissociation Profile

IV ketamine produces dissociation as a direct pharmacologic effect:

• Incidence: Highly variable (60–80%+ depending on dose)
• Onset: Within 5–15 minutes (faster than Spravato due to IV route)
• Peak: 30–45 minutes; more intense than Spravato
• Duration: 1–2 hours post-infusion; resolves by end of monitoring
• Severity: Often moderate-to-significant dissociation; some patients report profound out-of-body experiences
• Description: Intense perceptual distortion, feeling "disconnected," dream-like state, loss of bodily awareness
• Subjective experience: For some patients, dissociation is therapeutically valuable (associated with rapid symptom relief); for others, it's distressing and a barrier to continuing treatment

Other Common IV Ketamine Adverse Effects:

• Dizziness and vertigo
• Nausea and vomiting
• Sedation
• Tachycardia (increased heart rate)
• Hypertension
• Anxiety or panic during dissociation (less common with Spravato)

Clinical Implications: IV ketamine's more intense dissociation is part of its mechanism but can limit tolerability. Some patients find the dissociative experience psychologically valuable (insight, perspective shift); others find it distressing and discontinue treatment.

Cognitive Safety: Long-Term Implications

Spravato: Cognitive Preservation

A major advantage of Spravato (esketamine) is its long-term cognitive safety profile:

• Long-term data: Patients on esketamine for 6–12 months show maintained or slightly improved cognitive function (memory, attention, executive function)
• Mechanism: The S-enantiomer of ketamine may be neuroprotective; NMDA blockade + AMPA activation promotes neuroplasticity
• Clinical relevance: Safe for chronic use; no evidence of neurotoxicity with extended treatment
• Reversal on discontinuation: If cognitive changes occurred (rare), they resolve after stopping medication

Clinical Bottom Line: Spravato is safe for long-term, even indefinite, use from a cognitive perspective.

IV Ketamine: Cognitive Concerns

IV ketamine raises long-term cognitive safety questions, particularly with chronic use:

• Animal models: Chronic ketamine exposure in rodent studies shows evidence of neurotoxicity, neuroinflammation, and hippocampal damage
• Human clinical data: Limited but concerning reports of memory impairment, attention deficits, and cognitive decline with chronic IV ketamine (especially at higher cumulative doses)
• Mechanism concern: Racemic ketamine (1:1 mixture of R and S enantiomers) may have less selective NMDA antagonism than esketamine, potentially leading to off-target effects
• Chronic use: Unknown long-term safety profile; most users limit to acute/continuation phases (3–12 months)

Clinical Bottom Line: IV ketamine's long-term cognitive safety is uncertain. Providers often limit chronic use to 6–12 months, then discontinue or switch to alternative treatments due to unknown long-term risks.

This difference is critical for patients considering extended treatment beyond acute depression resolution.

Insurance Coverage & Cost

Spravato Insurance Coverage

Most major insurance companies now cover FDA-approved Spravato:

• Aetna: Covered
• BCBS: Covered
• Cigna: Covered
• UnitedHealthcare: Covered
• Medicare: Covered
• Optum, Oscar, First Health: Covered

Coverage Details:

• Prior authorization typically required
• Copay/coinsurance: $0–150/dose (varies by plan)
• Deductible usually applies first
• Annual out-of-pocket maximum applies

Self-Pay Cost at KwikPsych:

• Initial evaluation: $299
• Treatment dose: $179/dose
• Acute phase (8 doses): ~$1,432 + eval = ~$1,731 total

IV Ketamine Insurance Coverage

Most insurance companies DO NOT cover off-label IV ketamine:

• Reason: Off-label status; no FDA indication; insurers often deny claims
• Result: Patients pay entirely out-of-pocket
• Some exceptions: Medicare, military insurance, or specific state Medicaid plans may occasionally cover, but rare

Self-Pay Cost for IV Ketamine:

• Initial evaluation: $200–500
• Single infusion session: $500–1,500
• Acute phase (6–12 sessions): $3,000–18,000
• Maintenance doses (if chronic): $500–1,500/session

Cost Comparison Over 4-Week Acute Phase:

Insurance Winner: Spravato (with insurance coverage)

Which Is Right for You?

Choose Spravato If You:

• Have treatment-resistant depression that has failed 2+ antidepressant trials
• Have acute suicidal ideation (Spravato is FDA-approved for this indication)
• Have insurance coverage for Spravato (most major carriers do)
• Prefer intranasal vs. IV administration
• Concerned about long-term cognitive safety (Spravato is safer)
• Want an FDA-approved, REMS-certified treatment with robust regulatory oversight
• Can commit to in-office visits (cannot take home due to REMS)
• Live or work near a REMS-certified Spravato provider (like KwikPsych Austin)

Choose IV Ketamine If You:

• Have severe, acute TRD where even rapid response within hours is critical
• Have access to an experienced ketamine clinic with good safety track record
• Willing/able to pay out-of-pocket ($3,000–18,000 for acute phase)
• Prefer IV administration or have needle phobia addressed
• Want flexibility in treatment location (IV ketamine more widely available than Spravato)
• Limited insurance options and off-label use is not a concern
• Seeking higher efficacy expectations (though evidence is less robust)
• Planning short-term acute treatment only (6–12 months max) rather than long-term maintenance

Consider TMS Instead If You:

• Prefer non-medication approach to depression treatment
• Experience significant dissociation anxiety (TMS has zero dissociation)
• Have mild-to-moderate depression (TMS approved for these severity levels)
• Concerned about adverse effects in general (TMS side effects minimal)
• Have good insurance coverage (TMS widely covered; often $100–300/session copay)
• Living with psychotic depression (contraindicated for Spravato/ketamine)

Frequently Asked Questions

1. Which is actually more effective: Spravato or IV ketamine?

This is the $64,000 question. The honest answer: We don't know for certain.

Spravato evidence: Rigorous FDA-level randomized controlled trials showing 25–65% response rate in TRD.

IV ketamine evidence: Clinical reports, meta-analyses, and smaller studies suggesting 40–70% response, but less robust data.

Clinical reality: Anecdotally, some providers report ketamine produces faster/stronger initial response. Spravato offers more standardized, regulated treatment. Choose based on access, insurance, and personal preference, not presumed efficacy difference.

2. Can I get IV ketamine at home?

Some ketamine clinics offer at-home infusions, but this is not standard and raises safety concerns (no medical monitoring during infusion, medication administration non-standardized). Most experts recommend office-based IV ketamine with standard monitoring protocols.

Spravato, by REMS regulation, is never allowed at home—must always be office-based.

3. Does dissociation from Spravato or ketamine cause permanent brain damage?

No. Dissociation during a 2-hour Spravato session or IV ketamine infusion is a temporary, reversible state. By the end of monitoring, dissociation resolves. There is no evidence that acute dissociation causes structural brain damage or lasting cognitive problems.

Long-term concern: Chronic/repeated IV ketamine may carry cognitive risks with very high cumulative doses, but single-dose or short-term dissociation does not damage the brain.

4. Which treatment is safer long-term?

Spravato is safer long-term based on available evidence:

• Esketamine maintains/improves cognition with chronic use
• Racemic IV ketamine's long-term safety is uncertain; may impair cognition with chronic dosing
• Spravato has FDA oversight; IV ketamine does not

For short-term acute treatment (4–12 weeks), both are reasonably safe. For long-term maintenance (6+ months), Spravato has better safety data.

5. Can I switch from IV ketamine to Spravato or vice versa?

Yes, switching is possible, but:

• Some patients respond better to one than the other (individual variation)
• Switching requires washout period and re-evaluation
• Insurance/cost may change with switch
• Discuss with your psychiatrist; coordinate both providers if possible

6. What if I don't respond to Spravato or IV ketamine?

Treatment failure happens in 35–75% of patients, depending on treatment chosen. Options:

• Optimize dosing/frequency of current treatment
• Combine with medication adjustments or psychotherapy
• Trial alternative rapid-acting treatment (switch Spravato to ketamine or vice versa)
• Consider TMS, ECT, or other modalities
• Work with experienced psychiatrist to reassess and adjust plan

Disclaimer

This page is for informational purposes only and does not constitute medical advice. Both Spravato and IV ketamine are prescription treatments with significant risks, benefits, and contraindications. Information presented is based on FDA-approved labeling, clinical trial data, and peer-reviewed literature as of March 2026.

Do not start, stop, or change either treatment without medical supervision. Only a qualified psychiatrist can determine which treatment is appropriate for your individual situation.

For diagnosis, treatment planning, and clinical decisions, schedule a consultation with Dr. Monika Thangada at KwikPsych Austin (737-367-1230) or a qualified ketamine clinic.

References & Clinical Evidence

1. Spravato FDA Approval & Labeling

• U.S. Food and Drug Administration. (2019). Spravato (esketamine) nasal spray: Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243s000lbl.pdf

1. Spravato Clinical Trials

• Canuso, C. M., et al. (2018). "Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide." American Journal of Psychiatry, 175(7), 620–630.
• Popova, V., et al. (2019). "Efficacy and Safety of Flexibly-Dosed Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression." American Journal of Psychiatry, 176(6), 428–438.

1. IV Ketamine for Depression

• Zarate, C. A., et al. (2006). "A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression." Archives of General Psychiatry, 63(8), 856–864.
• Newport, D. J., et al. (2015). "Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression." American Journal of Psychiatry, 172(10), 950–966.

1. Esketamine vs. Racemic Ketamine

• Singh, J. B., et al. (2016). "Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study." Biological Psychiatry, 80(6), 424–431.

1. Cognitive Safety

• Daly, E. J., et al. (2019). "Safety and Efficacy of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression." JAMA Psychiatry, 76(6), 582–592.
• Shiroma, P. R., et al. (2014). "Augmentation of Antidepressants with Ketamine in Treatment-Resistant Depression." ISRN Psychiatry, 2014, 623819.

1. Long-Term Safety Concerns with Ketamine

• Vollenweider, F. X., & Kometer, M. (2010). "The Neuropharmacology of Hallucinogens and Related Drugs." Biological Psychiatry, 68(3), 256–267.

1. REMS Regulatory Framework

• FDA. (2020). Risk Evaluation and Mitigation Strategy (REMS) Guidance Documents. https://www.fda.gov/drugs/drug-safety-and-availability/rems

Learn more: Spravato Treatment  ·  Request an Appointment